{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:21:25Z","timestamp":1793136085456,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010754","name":"National Healthcare Group","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010754","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Eye Research"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.exer.2020.108187","type":"journal-article","created":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T21:20:01Z","timestamp":1597180801000},"page":"108187","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Potential of subconjunctival aflibercept in treating choroidal neovascularization"],"prefix":"10.1016","volume":"199","author":[{"given":"Jayabalan","family":"Nirmal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veluchamy A.","family":"Barathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Dickescheid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeo Sia","family":"Wey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali","family":"Nirmal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Moreno","family":"Raja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subbu","family":"Venkatraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupesh","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exer.2020.108187_bib1","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1167\/iovs.05-0492","article-title":"Transscleral-RPE permeability of PEDF and ovalbumin proteins: implications for subconjunctival protein delivery","volume":"46","author":"Amaral","year":"2005","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2020.108187_bib2","first-page":"1186","article-title":"Transscleral delivery of bioactive protein to the choroid and retina","volume":"41","author":"Ambati","year":"2000","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2020.108187_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/bjophthalmol-2014-305252","article-title":"Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD","author":"Avery","year":"2014","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.exer.2020.108187_bib4","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/eye.2011.225","article-title":"Potential penetration of topical ranibizumab (Lucentis) in the rabbit eye","volume":"25","author":"Chen","year":"2011","journal-title":"Eye"},{"key":"10.1016\/j.exer.2020.108187_bib5","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.2337\/diacare.26.9.2653","article-title":"Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies","volume":"26","author":"Ciulla","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.exer.2020.108187_bib6","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1167\/iovs.04-0496","article-title":"Interaction of lumican with aggrecan in the aging human sclera","volume":"45","author":"Dunlevy","year":"2004","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2020.108187_bib7","series-title":"Diagnostic Approach to Episcleritis and Scleritis, the Sclera","first-page":"59","author":"Foster","year":"1994"},{"key":"10.1016\/j.exer.2020.108187_bib8","first-page":"627","article-title":"Characterization of paracellular and aqueous penetration routes in cornea, conjunctiva, and sclera","volume":"38","author":"H\u00e4m\u00e4l\u00e4inen","year":"1997","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2020.108187_bib9","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1517\/14712598.2016.1167182","article-title":"The role of Aflibercept in the management of age-related macular degeneration","volume":"16","author":"Hassan","year":"2016","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.exer.2020.108187_bib10","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1056\/NEJMra0801537","article-title":"Age-related macular degeneration","volume":"358","author":"Jager","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.exer.2020.108187_bib11","first-page":"2803","article-title":"FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye","volume":"15","author":"Kim","year":"2009","journal-title":"Mol. Vis."},{"key":"10.1016\/j.exer.2020.108187_bib12","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000108117","article-title":"Transport barriers in transscleral drug delivery for retinal diseases","volume":"39","author":"Kim","year":"2007","journal-title":"Ophthalmic Res."},{"key":"10.1016\/j.exer.2020.108187_bib13","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/jps.20178","article-title":"Antibody pharmacokinetics and pharmacodynamics","volume":"93","author":"Lobo","year":"2004","journal-title":"J. Pharmaceut. Sci."},{"key":"10.1016\/j.exer.2020.108187_bib14","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ejpb.2016.09.003","article-title":"Study of stability and biophysical characterization of ranibizumab and aflibercept","volume":"108","author":"Moreno","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.exer.2020.108187_bib15","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1080\/17425247.2016.1188800","article-title":"Drug, delivery and devices for diabetic retinopathy (3Ds in DR)","volume":"13","author":"Nirmal","year":"2016","journal-title":"Expet Opin. Drug Deliv."},{"key":"10.1016\/j.exer.2020.108187_bib16","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1167\/iovs.08-3148","article-title":"Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits","volume":"50","author":"Nomoto","year":"2009","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2020.108187_bib17","first-page":"1893","article-title":"Human scleral permeability. Effects of age, cryotherapy, transscleral diode laser, and surgical thinning","volume":"36","author":"Olsen","year":"1995","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2020.108187_bib18","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1167\/iovs.10-6291","article-title":"Pharmacokinetics of pars plana intravitreal injections versus microcannula suprachoroidal injections of bevacizumab in a porcine model","volume":"52","author":"Olsen","year":"2011","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2020.108187_bib19","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1167\/iovs.16-19204","article-title":"Intraocular pharmacokinetics of intravitreal aflibercept (Eylea) in a rabbit model","volume":"57","author":"Park","year":"2016","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2020.108187_bib20","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1167\/iovs.13-12574","article-title":"Expression of neonatal Fc receptor in the eye","volume":"55","author":"Powner","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2020.108187_bib21","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.drudis.2016.10.015","article-title":"Protein delivery to the back of the eye: barriers, carriers and stability of anti-VEGF proteins","volume":"22","author":"Radhakrishnan","year":"2017","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.exer.2020.108187_bib22","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jconrel.2010.08.028","article-title":"Barrier analysis of periocular drug delivery to the posterior segment","volume":"148","author":"Ranta","year":"2010","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.exer.2020.108187_bib23","first-page":"725","article-title":"Conjunctival and episcleral blood vessels are permeable to blood-borne horseradish peroxidase","volume":"24","author":"Raviola","year":"1983","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2020.108187_bib24","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.exer.2020.108187_bib25","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2174\/187152811798104872","article-title":"Aflibercept (VEGF-TRAP): the next anti-VEGF drug","volume":"10","author":"Stewart","year":"2011","journal-title":"Inflamm. Allergy - Drug Targets"},{"key":"10.1016\/j.exer.2020.108187_bib26","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s10456-017-9591-4","article-title":"AAV-mediated gene delivery of the calreticulin anti-angiogenic domain inhibits ocular neovascularization","volume":"21","author":"Tu","year":"2018","journal-title":"Angiogenesis"},{"key":"10.1016\/j.exer.2020.108187_bib27","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.exer.2020.108187_bib28","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.bbrc.2011.04.014","article-title":"Comparing protein VEGF inhibitors: in vitro biological studies","volume":"408","author":"Yu","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."}],"container-title":["Experimental Eye Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483520304450?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483520304450?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T05:06:15Z","timestamp":1757999175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014483520304450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":28,"alternative-id":["S0014483520304450"],"URL":"https:\/\/doi.org\/10.1016\/j.exer.2020.108187","relation":{},"ISSN":["0014-4835"],"issn-type":[{"value":"0014-4835","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential of subconjunctival aflibercept in treating choroidal neovascularization","name":"articletitle","label":"Article Title"},{"value":"Experimental Eye Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exer.2020.108187","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108187"}}